It is being suggested that a no-deal Brexit would put an end to parallel imports to the UK, thereby reducing price competition and pushing up costs of medicines prescribed on the NHS.
A no-deal Brexit would eliminate parallel trade between the UK and the EU, and the resulting lack of competition from cheaper imported medicines would inevitably lead to higher drug prices for the National Health Service, according to the UK body representing parallel traders.
Richard Freudenberg, head of the British Association of European Pharmaceutical Distributors, told a hearing of the UK House of Lords...
<p>Executive Summary</p> <p>A list of EU biosimilar filings, CHMP opinions and EU marketing authorizations, including details of the biosimilar company, the brand name/INN, indication(s), the reference product/company, and the date and type of event.</p>
As the reform of the EU pharmaceutical legislation progresses through the legislative process, the Pinks Sheet offers an infographic highlighting some of the key changes being proposed that will reshape the way drug companies run their business.
<p>Executive Summary<p> <p>The Pink Sheet's list of EU centralized approvals of new active substances has been updated to add six new products, incl/ding Ixchiq, Valneva's chikungunya virus vaccine</p>
A new research ethics review system for multi-site clinical trials in Canada is expected to help improve study start-up times, avoid unnecessary duplication and boost the country’s competitiveness on a global stage.
With the deadline for comments on the US FDA’s draft guidance less than a month away, the Pink Sheet offers an infographic outlining what the agency is expecting in diversity action plans and when that might be implemented.
